Voyager Therapeutics, Inc. (VYGR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VYGR currently has 59.5M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 34.09% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 59.5M shares outstanding |
59M | 0 |
| Mar 09, 2026 |
10-K filing | 58.7M shares outstanding |
59M | 0 |
| Aug 06, 2025 |
10-Q filing | 58.7M shares outstanding |
59M | 0 |
| May 06, 2025 |
10-Q filing | 58.3M shares outstanding |
58M | 0 |
| Mar 11, 2025 |
10-K filing | 57.7M shares outstanding |
58M | 0 |
| Nov 12, 2024 |
10-Q filing | 44.0M shares outstanding |
44M | 0 |
| Aug 06, 2024 |
10-Q filing | 44.0M shares outstanding |
44M | 0 |
| May 13, 2024 |
10-Q filing | 44.0M shares outstanding |
44M | 0 |
| Mar 13, 2024 |
8-K filing: Voyager Therapeutics, Inc. appointed Toby Ferguson, M.D., Ph.D. as Chief Medical Officer, effective March 25, 2024, and granted him a stock option to purchase 210,000 shares and a restricted stock unit award representing the right to receive 105,000 shares of the Company's common stock. |
45M | 0 |
| Feb 28, 2024 |
10-K filing | 44.6M shares outstanding |
45M | 0 |
| Jan 08, 2024 |
8-K filing: Voyager Therapeutics, Inc. completed a public offering of 7,777,778 shares of common stock and pre-funded warrants to purchase 3,333,333 shares, and also closed a private placement with Novartis for 2,145,002 shares at $9.324 per share. ($20.0M proceeds) |
39M | 0 |
| Nov 06, 2023 |
10-Q filing | 38.6M shares outstanding |
39M | 0 |
| Aug 03, 2023 |
10-Q filing | 38.6M shares outstanding |
39M | 0 |
| Jul 10, 2023 |
8-K filing: Voyager Therapeutics, Inc. appointed Jacquelyn Fahey Sandell as Chief Legal Officer, effective July 10, 2023, granting her a stock option to purchase 122,000 shares and a restricted stock unit award for 61,000 shares. |
41M | 0 |
| May 09, 2023 |
10-Q filing | 40.6M shares outstanding |
41M | 0 |
| Mar 07, 2023 |
10-K filing | 38.4M shares outstanding |
38M | 0 |
| Nov 08, 2022 |
10-Q filing | 38.5M shares outstanding |
39M | 0 |
| Nov 08, 2022 |
S-3 filing: Voyager Therapeutics, Inc. is offering securities from time to time in one or more offerings of up to $300,000,000 in aggregate offering price. |
39M | 0 |
| Sep 07, 2022 |
8-K filing: Appointment of Todd Carter, Ph.D. as Chief Scientific Officer and Trista Morrison as Senior Vice President of Corporate Affairs and Chief of Staff to the Chief Executive Officer. |
38M | 0 |
| Aug 04, 2022 |
10-Q filing | 38.3M shares outstanding |
38M | 0 |
| May 04, 2022 |
10-Q filing | 38.0M shares outstanding |
38M | 0 |
| Mar 08, 2022 |
10-K filing | 37.7M shares outstanding |
38M | 0 |
| Nov 02, 2021 |
10-Q filing | 37.8M shares outstanding |
38M | 0 |
| Aug 09, 2021 |
10-Q filing | 37.4M shares outstanding |
37M | 0 |
| May 10, 2021 |
10-Q filing | 37.7M shares outstanding |
38M | 0 |
| Feb 25, 2021 |
10-K filing | 37.3M shares outstanding |
37M | 0 |
| Nov 09, 2020 |
10-Q filing | 37.2M shares outstanding |
37M | 0 |
| Aug 10, 2020 |
10-Q filing | 37.0M shares outstanding |
37M | 0 |
| May 06, 2020 |
10-Q filing | 37.2M shares outstanding |
37M | 0 |
| Mar 03, 2020 |
10-K filing | 32.4M shares outstanding |
32M | 0 |